Brand Reference: Aricept
| Metric | Verified Benchmark | Source |
|---|---|---|
| Donepezil Hydrochloride RxNorm Concept ID | 135447 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0440 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $44.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.30 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $6.80 / mo | 14 Zero-PHI Verified Patient Logs |
Displays >1,000-fold selectivity for central nervous system acetylcholinesterase over peripheral plasma butyrylcholinesterase, slowing synaptic acetylcholine hydrolysis across basal forebrain-to-hippocampal cholinergic memory projections.
For self-pay patients filling Donepezil Hydrochloride (NDC 00378-2005-93), direct wholesale and telehealth fulfillment drops monthly spend from $44.00 retail to $5.30 (88% savings against a $0.0440 CMS pharmacy acquisition baseline).
Clinical clearance of Donepezil Hydrochloride (Piperidine Reversible Central Acetylcholinesterase Inhibitor) relies on cyp2d6 and cyp3a4 o-dealkylation plus 57% urinary excretion with a 70 hours half-life; patients absorbing at 100% oral bioavailability typically observe target onset around 3–6 weeks cholinergic steady state.
FDA clinical labeling for Donepezil Hydrochloride restricts administration in sick sinus syndrome or sinoatrial/av vagotonic conduction block; active peptic ulcer bleeding across 5 mg PO QHS x 4–6 weeks, 10 mg PO QHS, with self-reported patient tracking dominated by vivid cholinergic rem dreams (24% of reports), loose stools / nausea (18% of reports), resting bradycardia (9% of reports).
Across 14 verified cash-pay logs, Donepezil Hydrochloride achieves a 79.60% Worth-It rating with out-of-pocket spend averaging $6.80/mo versus $44.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO QHS x 4–6 weeks for Donepezil Hydrochloride; monthly out-of-pocket dropped to $4.66 compared with $44.00 retail.
Completed 10 weeks on Donepezil Hydrochloride (10 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO QHS x 4–6 weeks Donepezil Hydrochloride sourced via Cash Clinic ($6.15/mo cash pay without insurance prior authorization).